echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Shanghai Municipal Public Health Clinical Center completed the clinical study of PD-L1 antibody ASC22 (envorizumab) combined with sidabenamide for functional cure of HIV infection

    Shanghai Municipal Public Health Clinical Center completed the clinical study of PD-L1 antibody ASC22 (envorizumab) combined with sidabenamide for functional cure of HIV infection

    • Last Update: 2022-10-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Gorillace Pharmaceutical Limited (HKEx: 1672, "Graeley") announced the completion


    The study (clinical trial registration number: NCT05129189) aimed to evaluate the efficacy


    The experimental regimen was 1 mg/kg ASC22 (envorizumab) every 4 weeks in combination with 10 mg cedabenamide tablets twice weekly for 12 weeks


    ASC22 (envorizumab) is a subcutaneously injected PD-L1 single-domain antibody that has the potential


    "The clinical study of ASC22 (envorizumab) and cedabenamide for functional cure of human immunodeficiency virus (HIV) infection completed the first patient enrollment on July 1 this year, and I am very pleased that this study completed the enrollment of all patients in less than 3 months


    Although standard antiretroviral therapy is becoming widespread and improving, functional cures for people living with HIV remain a challenge in China and around the


    Dr.


    Gorillace Pharmaceutical Limited (HKEx: 1672, "Graeley") announced the completion


    The study (clinical trial registration number: NCT05129189) aimed to evaluate the efficacy


    The experimental regimen was 1 mg/kg ASC22 (envorizumab) every 4 weeks in combination with 10 mg cedabenamide tablets twice weekly for 12 weeks


    ASC22 (envorizumab) is a subcutaneously injected PD-L1 single-domain antibody that has the potential


    "The clinical study of ASC22 (envorizumab) and cedabenamide for functional cure of human immunodeficiency virus (HIV) infection completed the first patient enrollment on July 1 this year, and I am very pleased that this study completed the enrollment of all patients in less than 3 months


    Although standard antiretroviral therapy is becoming widespread and improving, functional cures for people living with HIV remain a challenge in China and around the


    Dr.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.